COVID-19: vaccination problems
- PMID: 33928745
- PMCID: PMC8209888
- DOI: 10.1111/1462-2920.15549
COVID-19: vaccination problems
Abstract
This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned.
© 2021 Society for Applied Microbiology and John Wiley & Sons Ltd.
References
-
- Anonymus (2020). Eyes of the world are on medicines regulators. Nature 588: 195. - PubMed
-
- Anonymous . (2021a) Science advisers: publish evidence behind COVID vaccine dosing strategy. Nature 588: 195. - PubMed
-
- Bernal, J. L. , Andrews, N. , Gower, C. , Stowe, J. , Robertson, C. , Tessier, E. , et al. (2021) Early effectiveness of COVID‐19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv preprint. URL https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical